Key clinical point: Most elderly patients with primary central nervous system lymphoma can tolerate methotrexate-based chemotherapy and achieve similar outcomes as younger and fitter patients.

Major finding: Treatment-related mortality for patients given high-dose methotrexate-based chemotherapy was 6.8%.

Study details: A retrospective study involving 244 patients with primary central nervous system lymphoma aged at least 65 years.

Disclosures: Dr. Poynton reported having no relevant financial disclosures. His coinvestigators reported relationships with AbbVie, Merck, Takeda, Jazz Pharmaceuticals, and others.